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Abstract
Small molecules that increase the presynaptic function of aminergic cells may provide 
neuroprotection in Parkinson’s disease as well as treatments for attention deficit hyperactivity 
disorder (ADHD) and depression. Model genetic organisms such as Drosophila melanogaster may 
enhance the detection of new drugs via modifier or “enhancer/suppressor” screens, but this 
technique has not been applied to processes relevant to psychiatry. To identify new aminergic 
drugs in vivo, we used a mutation in the Drosophila vesicular monoamine transporter (dVMAT) as 
a sensitized genetic background, and performed a suppressor screen. We fed dVMAT mutant 
larvae ~1000 known drugs and quantitated rescue (suppression) of an amine-dependent locomotor 
deficit in the larva. To determine which drugs might specifically potentiate neurotransmitter 
release, we performed an additional secondary screen for drugs that require presynaptic amine 
storage to rescue larval locomotion. Using additional larval locomotion and adult fertility assays, 
we validated that at least one compound previously used clinically as an antineoplastic agent 
potentiates the presynaptic function of aminergic circuits. We suggest that structurally similar 
agents might be used to development treatments for Parkinson’s disease, depression and ADHD 
and that modifier screens in Drosophila provide a new strategy to screen for neuropsychiatric 
drugs. More generally, our findings demonstrate the power of physiologically based screens for 
identifying bioactive agents for select neurotransmitter systems.
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Introduction
Most antidepressants and treatments of ADHD target the same proteins, mandating the 
development of novel screening strategies. Current treatments for Parkinson’s disease (PD) 
are also limited and do not slow the underlying neurodegenerative process. The presynaptic 
proteins required for the exocytotic release of monoamines may serve as novel therapeutic 
targets for both of these illnesses. These include the release machinery itself, the vesicular 
monoamine transporter (VMAT), required for transport of all amines into synaptic vesicles, 
and other proteins that regulate these activities (1). Multiple studies support the potential 
clinical relevance of these targets. VMAT regulates cytosolic concentrations of dopamine 
(DA), and the cytosolic pool of DA is neurotoxic (2, 3). Loss of VMAT2 increases DA cell 
death (4) whereas over-expression of VMAT is neuroprotective (5, 6). Inhibition of VMAT 
causes a state resembling depression (7, 8), and overexpression of VMAT mimics the effects 
of psychostimulants (9). To date, drugs that increase the activity or expression of VMAT are 
not known. More generally, with the exception of the DA precursor L-DOPA, which 
increases DA storage via increased synthesis, current psychotropic drugs are not able to 
increase the exocytotic release of biogenic amines via other mechanisms. Amphetamines, by 
contrast, use alternative mechanisms to release biogenic amines, including efflux through 
the plasma membrane dopamine transporter, and may be neurotoxic (10).
“Enhancer/suppressor”, or “modifier” screens in Drosophila melanogaster are a powerful 
method to identify novel genes or drugs in biological pathways of interest (11). To our 
knowledge, this strategy has not yet been used to identify drugs relevant to psychiatry, and 
relatively few screens have been reported for models of PD or other neurological diseases. 
Here we have used the dVMAT larval phenotype as a sensitized genetic background to 
screen for aminergic drugs and performed additional genetic tests to narrow potential 
mechanisms. We suggest that this strategy represents a new way to screen for psychotropic 
drugs in an intact organism without bias toward known drug targets and demonstrate its use 
to identify a possible new class of aminergic drugs.
Materials and Methods
Drosophila strains and maintenance
All mutations and transgenes have been described previously, including the null dVMAT loss 
of function mutant dVMATP1 (12), the UAS-DVMAT-A transgene (9) and the tyramine β-
hydroxylase (TβH) mutant (13). All lines were outcrossed for five generations into either the 
wild-type strain Canton S (CS), or w1118 CS10 (w1118 outcrossed 10 times to CS) and 
maintained at 25°C on standard cornmeal molasses agar media in a 12 hr light dark cycle.
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Drug exposure
Initial screens were performed using a library of 1039 drugs (10 mM) solubilized in 
dimethylsulfoxide (DMS0) (US Drug collection from Microsource Discovery systems, 
Gaylordsville, CT) and additional chemicals were used for validation assays as indicated 
(Sigma-Aldrich, St. Louis, MO). All drugs were added with vigorous mixing to molten 
cornmeal molasses agar media to a final concentration of ≤ 1% DMSO with food coloring 
(1% v/v, Kroger, Cincinnati, OH) to confirm feeding. Larva homozygous for dVMATP1 (+/
−UAS-DVMAT, see text) were use for all assays and differentiated from dVMATP1/CyO 
siblings based on the observed rate of locomotion.
Larval locomotion assay
Two to three larvae were placed on the food/drug mixture for 30 sec to acclimate and 
locomotion was scored as the number of 0.4 cm grids crossed over a 2 min period (time 0). 
After additional incubation on the drug/food mixture for 2 hrs and 24 hrs (23°C) assays were 
repeated.
Fertility Assay
Three virgin females (0–3 day old) were mated with six CS males (0–3 days old) for three 
days on standard food then transferred to fresh food containing the indicated drug plus 1% 
food coloring (Kroger Foods, Cincinatti, OH). Eggs laid over the ensuing 24 hr period were 
counted.
Results
Weak expression of ‘leaky’ DVMAT generates a functional hypomorph
Octopamine (OA) is required for the initiation and regulation of baseline motor behavior in 
Drosophila larva (14). OA is thought to play a role in invertebrates similar to that of 
mammalian noradrenalin but is synthesized via a different enzymatic pathway and contains 
one rather than two ring oxygens (15). In addition to OA, dopaminergic circuits can 
influence locomotion under conditions of low OA and are responsible for the effects of 
several psychostimulants (16). Locomotor rates of wild type larvae are relatively high at 
baseline making it difficult to detect the effects of exogenously applied amines (Fig. 1a) or 
known aminergic drugs (data not shown). In contrast, dVMATP1 null larvae show severely 
reduced baseline larval locomotion (12), and dVMATP1 larvae fed OA show a robust and 
easily quantified increase in baseline locomotion (Fig. 1b). We reasoned that the dVMAT 
mutant might also be used as a sensitized genetic background to screen for novel aminergic 
drugs.
To allow the identification of drugs that require might act presynaptically, we developed a 
sensitized background that retained some degree of presynaptic function. We crossed into 
the dVMATP1null background a leaky UAS-DVMAT transgene that expresses low levels of 
DVMAT in the absence of an additional exogenous Gal4 driver (6). We designate this line 
(dVMATP1; UAS-DVMAT) the dVMAT “weak expressor”. Locomotion rates of the “weak 
expressor” are low relative to wt but significantly higher than the dVMAT null (Fig. 1c). To 
confirm that the dVMAT weak expressor would respond to drugs that act presynaptically, we 
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used amphetamine, which promotes the presynaptic release of monoamines in both 
mammals (10) and flies (16). Amphetamine feeding caused a dose-dependent increase in 
locomotion in the dVMAT weak expressor, but not the dVMAT null (Fig. 1d).
Locomotion based primary screen
In our primary screen (Fig. 1e) we tested whether any of 1039 drugs (Table S1) would 
increase locomotion in the dVMAT weak expressor, using two concentrations of each drug 
(10 and 100 uM). Locomotion was assayed before ingestion (0 hrs) and after 2 and 24 hrs of 
incubation on food containing each drug. A photo of an assay plate (Fig. 1f) and a 
representative sample of data from the primary screen is shown (Fig. 1g, See Table S1 for 
names of all 1039 tested drugs and Fig. S1 for primary screen data). Averaging across all 
drugs and vehicle controls, the mean+/−SD grid lines traveled over 2 min at 0, 2 and 24 hrs 
was 1.18+/−0.86, 1.33+/−1.09 and 1.13+/−1.2 respectively (n=2193). We identified 40 
“strong hits” as drugs that increased locomotion at either 2 or 24 hr and either 10 or 100 uM 
>3.5 SD (>4.2 grid lines) above the mean at time 0 (Fig. 2a–d). An additional 76 drugs were 
scored as “weak hits”: locomotion >2 but < 3.5 SD above the mean (>2.9 and < 4.2 gridlines 
per 2 min, Table S2).
Secondary screen
The drugs identified in our primary screen could act at several distinct sites in the 
locomotion circuit, but can be distinguished by their requirement for amine storage and 
release (Fig. 2e). Those acting presynaptically in aminergic cells or other upstream sites in 
the CNS will require DVMAT to allow amine storage. These “DVMAT dependent” drugs 
will stimulate movement in the dVMAT weak expressor but not the null. Conversely 
“DVMAT independent” drugs that act post-synaptically at the aminergic synapse(s) that 
stimulate larval locomotion (14, 16) or downstream sites will not require DVMAT for amine 
storage and release and will stimulate movement in both the DVMAT weak expressor and 
the null.
Of 40 strong hits from the primary screen, 15 were unable to stimulate movement in the 
dVMAT null mutant in the secondary screen (Table S3). These drugs were tentatively 
designated as DVMAT-dependent. In contrast, 11 drugs that strongly stimulated locomotion 
in the primary screen also strongly stimulated locomotion in the dVMAT null in the 
secondary screen and were tentatively designated as DVMAT independent (Table S3). A 
third group of 14 drugs weakly stimulated movement in the dVMAT null in the secondary 
screen and thus did not clearly fall into either the DVMAT dependent or independent 
category (Table S3). To facilitate further analysis, we focused on those that were either 
DVMAT dependent or independent rather than these more ambiguous candidates.
Validation of candidates from primary and secondary screens
To validate the results of our primary and secondary screens, we obtained from commercial 
sources 13 of 15 DVMAT dependent drugs (Table S4 lists other drugs that were not 
available). Six of these were validated to stimulate locomotion in the weak expressor (Fig. 
3a, top panel) but not the null (Fig. 3a, bottom panel). An additional class of 2 drugs (Fig. 
3c) paradoxically showed increased locomotion in the dVMAT null but not the weak 
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expressor and were not pursued. Four of the drugs tentatively identified as DVMAT 
independent (and commercially available) were validated as able to stimulate locomotion in 
both the dVMAT null and the weak expressor (Fig. 3d). In addition, 2 drugs tentatively 
identified as DVMAT dependent were reclassified as DVMAT independent (Fig. 3e) 
bringing the total to 6 (Table 1). Retesting a subset of five weak hits from our primary 
screen (Fig. 3g) identified only one additional DVMAT dependent drug for a total of 7 
(Table 1). Since our yield was relatively low, we did not attempt to validate any additional 
“weak” hits.
Several hits identified in our original screen could not be replicated during validation and, as 
noted above, three others were reclassified. There are several possible reasons why the 
results of our validation assays were not completely consistent with our initial screens. 
These include: 1) experimental error resulting from the manual collection of data by 
different individuals; 2) differences between the formulation, purity and degree of 
degradation between the drugs used in our initial screens which were from a commercial 
library, versus those used in the validation assays which were purchased from a separate 
source. Future screening efforts will employ an automated data collection system (not 
shown) reducing at least one potential source of varialbility.
Validated hits (Table 1) included several cholinergic compounds, consistent with the known 
role of acetylcholine in Drosophila locomotion and the cholinergic input to larval 
motoneurons (17, 18) (See Fig. 2e). Others appeared to represent a range of drugs with 
varied known uses (Table 1). The mode of action of these drugs in our assay may or may not 
be similar to the activity for which they are currently used. To address this issue and provide 
preliminary mechanistic information, we selected for further analysis one of the 7 validated 
DVMAT dependent drugs and one of the 6 DVMAT independent drugs. We focused on 
drugs able to give a robust signal at the 2 hr time point during the validation phase rather 
than those than only stimulated locomotion after 24 hrs since the former would be more 
likely to act via relatively direct mechanisms as opposed to long-term changes in 
transcription. Of the DVMAT independent drugs, we focused on pergolide, a known amine 
receptor agonist in mammals (see below). Of the DVMAT dependent drugs, we focused on 
dacarbazine, previously used only as an anticancer drug (19) rather than a psychotropic.
Further tests of pergolide and dacarbazine
Additional dose response experiments show that both dacarbazine (Fig. 4a) and pergolide 
(Fig. 4b) increase locomotion at concentrations up to 0.5–1mM in the weak expressor. To 
determine whether pergolide and dacarbazine were generally active as aminergic agents in 
the fly, we tested their affects on another amine-dependent behavior: egg-laying in the adult. 
This behavior is controlled predominantly by OA (13, 20–23) although oocyte development 
may be regulated in part by DA (24). Consistent with its assignment as a DVMAT 
independent drug in larval locomotion assays, pergolide at 1mM partially rescued egg laying 
in both the dVMAT null and weak expressors (Fig. 4c). By contrast, 1mM dacarbazine 
rescued egg-laying in the dVMAT weak expressor but had no effect in the null mutant (Fig. 
4d), thus demonstrating that it acts in a DVMAT dependent fashion in at least two 
independent circuits in larvae and adults.
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Since the sensitized background used in out primary screen employs a “leaky” UAS-
DVMAT transgene that is expressed at low levels in the absence of a cell-specific Gal4 
driver, it should allow low levels of amine storage and release from all types of aminergic 
neurons including those that synthesize DA, 5-HT and OA. However, since baseline larval 
locomotion and egg-laying are primarily regulated by OA (13, 14, 20, 21) we focused 
further mechanistic experiments on OA circuits. We first tested the effects of the OA 
receptor antagonists mianserin and epinastine (25, 26). (Both decrease the locomotion of CS 
larvae, Fig. S2). dVMAT null larvae were fed 1uM pergolide for 2h, followed by mianserin, 
epinastine or vehicle alone. Pergolide continued to stimulate locomotion after transfer to 
food containing vehicle alone (Fig. 4e, f). In contrast, although neither drug completely 
abolished the effect of pergolide, transfer to food containing mianserin or epinastine reduced 
the locomotor effects of pergolide by 60% (****p<0.0001 two-way ANOVA; ***p<0.001, 
Bonferroni post test) and 33% (***p<0.0001, two-way ANOVA; *p<0.05, Bonferroni post 
test) respectively (Fig. 4e, f, compare first black bars to second black bars). In support of the 
specificity of mianserin and epinastine for OA circuits, we tested these drugs on tyramine 
beta hydroxylase (TbH) mutants and found no effect (not shown). The simplest explanation 
of our results is that pergolide can act in part as an OA receptor agonist in Drosophila, in 
addition to its activity as a D2 receptor agonist in mammals (27) and that activation of OA 
receptors by pergolide stimulates larval locomotion.
To determine whether OA synthesis is required for dacarbazine or pergolide to stimulate 
locomotion, we used the tyramine beta hydroxylase (TbH) mutant, which is unable to 
convert the precursor tyramine to OA (13). Homozygous TbH mutants show defects in 
larval locomotor behavior consistent with a requirement for OA (14, 28). Dacarbazine had 
no effect on locomotion behavior in the TbH null (Fig. 4h) as compared to the dVMAT weak 
expressor control. In contrast, pergolide (Fig. 4i) increased larval locomotion in both the 
TbH null and the dVMAT weak expressor. These results further suggest that dacarbazine 
may act within the OA cell itself to stimulate the amine storage and release, or at a site in the 
nervous system upstream of the OA cell that regulates baseline locomotion.
A structural analog of dacarbazine increases locomotion in the dVMAT weak expressor 
but not in the dVMAT null
Dacarbazine is currently used as an antineoplastic agent (29). Toxic effects would limit its 
use as a psychotropic in mammals, and high doses are toxic to fly larvae (Fig. S3). In 
mammals, dacarbazine is metabolized to methyldiazonium, which mediates DNA alkylation, 
plus the non-toxic 5-amino-4-imidazole-carboxamide (AICA) backbone (29) (see Fig. 4j). 
Unlike dacarbazine, AICA does not show toxicity in the fly at high concentrations (Fig. S3). 
However, similar to dacarbazine, AICA increases locomotion in a dose-dependent fashion 
after either 2 hr (Fig. 4k) or 4 hr exposure (Fig. S4) in the dVMAT weak expressor but not 
the dVMAT null (Figs. S4). One available derivative of AICA is 5-aminoimidazole-4-
carboxamide 1-β-D-ribofuranoside (AICAR, Fig. 4j) a potential antihyperglycemic agent 
thought to act in part via stimulation of AMP kinase (30). In contrast to AICA, AICAR did 
not increase locomotion in the dVMAT weak expressor at 2 hrs or 4 hrs in either the weak 
expressor or the null (Fig. 4l and S4).
Lawal et al. Page 6
Mol Psychiatry. Author manuscript; available in PMC 2014 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Discussion
We describe here the use of a “modifier” or “enhancer/suppressor” screen for psychotropic 
drugs in Drosophila melanogaster. Screening for a change in functional output in an intact 
animal selects for targets that are physiologically relevant, and selects for drugs that are able 
penetrate a glial barrier to enter the CNS (31). The use of a sensitized background (here the 
dVMAT mutant) focused our screen on a specific biological process (aminergic signaling) 
without limiting the range of protein targets. The sensitized genetic background also allowed 
the detection of pharmacologic activities that are difficult to observe in the wild type. We 
are not aware of any previous studies using this method to screen for aminergic drugs or any 
other small molecules relevant to the treatment of psychiatric illness.
Importantly, we have identified drugs that give a desirable functional effect without 
selecting for a specific protein target. We recognize that additional experiments will be 
needed to determine the mechanism of action of any drugs identified in this manner. 
However, we emphasize that because of the unbiased nature of our screen, the potential 
mechanisms will not be restricted to known drug targets. We therefore propose that this 
approach will complement other existing methods of drug discovery in which specific 
protein targets are preselected, and may allow the detection of drugs that act on novel targets 
unrelated to those already used for the treatments for depression, ADHD and PD.
In preliminary transport experiments, we have not been able to detect a direct effect of 
dacarbazine on VMAT transport activity (data not shown). Indeed, we are not aware of any 
psychotropic drugs that can directly increase the physiological activity of a neurotransmitter 
transporter. Rather we suggest that the drugs we identify are more likely to increase VMAT 
activity in an indirect fashion. We suggest that the strength of our system, and the use of an 
in situ aminergic circuit, is that it will allow the detection of drugs that act on a variety of 
novel targets that act upstream of VMAT, or may otherwise increase amine release via other 
indirect mechanisms. We further suggest that such targets may not be present in less 
complex screening platforms, and because they indirectly stimulate neurotransmission, may 
not be obvious “aminergic” targets for drug development.
Although we used an octopaminergic circuit in our screen, some of the drugs we have 
identified may be generally active at other types of aminergic nerve terminals, similar to 
DVMAT and mammalian VMAT2, which are expressed broadly in most if not all aminergic 
neurons in the CNS (1, 32). Since the molecular mechanisms of monoamine release are 
conserved across many species, it is also possible that some drugs will be active in 
mammalian systems. Indeed, assays of peripheral blood in rodents and patients treated with 
dacarbazine demonstrate an increase in peripheral 5HT metabolites, due to release of 5HT 
from enterochromaffin cells (33, 34). These observations support the notion that at least 
some of the drugs we have identified may be active across multiple types of aminergic 
neurons and have similar effects in mammals.
Since dacarbazine is used as a chemotherapeutic to kill dividing cells (29) it is unlikely to be 
directly useful as a psychotropic or neuroprotective agent. We find that 5-
Aminoimidazole-4-carboxamide (AICA), which lacks an alkylating moiety but is otherwise 
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identical to dacarbazine, mimics its activity in the fly. Another derivative, 5-
Aminoimidazole-4-carboxamide 1-β-D-ribofuranoside (AICAR), which is undergoing trials 
as an antihyperglycemic agent (30, 35) did not stimulate locomotion. It is likely that 
additional derivatives will need to be developed if this class of molecules is to be 
investigated for its potential effects in mammals.
In conclusion, our data support the use of modifier screens in the fly to identify novel 
aminergic agents. If any of the drugs we have identified or structurally related derivatives 
are found to increase amine release in mammals they might be used to treat depression or 
ADHD. Increasing amine storage in vesicles also has the potential to sequester cytotoxic DA 
metabolites away from their site of action (36). Thus, some identified drugs might provide 
novel neuroprotective strategies for PD (5, 6, 37). In support of this possibility, preliminary 
data suggest that a subset of DVMAT-dependent drugs can increase the survival of 
mammalian dopaminergic neurons in culture (data not shown). More generally, we suggest 
that modifier screens in Drosophila provide a new way to screen for psychotropic drugs 
without bias toward previously identified protein targets. Similar screens also might be used 
to identify novel GABAergic or glutamatergic agents.
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Figure 1. Screen design
Baseline locomotion is unchanged in wild type larvae (A) but increased in dVMAT mutant 
larvae fed octopamine (panel B, OA) or vehicle for 2 hrs (1 way ANOVA *p<0.05, n=10 
larvae per condition. (C) Locomotion of the dVMAT weak expressor shows a slight increase 
relative to the dVMAT null mutant but is severely reduced compared to wt larvae (one-way 
ANOVA p<0.0001, Bonferroni post test, ***p<0.001, mean+/− SEM, n=30–31). (D) 
Feeding amphetamine increases locomotion in the dVMAT weak expressor but not the null 
(one-way ANOVA p<0.05, Bonferroni post test *p<0.05, mean +/−SEM, n=8–9 larvae. (E) 
Screening strategy. In our Primary Screen we assayed drugs for their ability to increase or 
“rescue” the deficit in locomotion seen in larvae expressing low levels of DVMAT (the 
dVMAT “Weak Expressor”). In the Secondary Screen, candidate drugs were tested for their 
ability to increase locomotion in the dVMAT null. Drugs able to rescue locomotion in both 
the Primary and Secondary screens were designated “DVMAT independent” and therefore 
potentially acting via post-synaptic mechanisms. Conversely, drugs able to rescue 
locomotion in the Primary but not the Secondary screen were designated as “DVMAT 
dependent” and potentially acting via presynaptic mechanisms to increase amine release. 
During the Validation Phase of the screen, candidates were retested and either confirmed as 
DVMAT dependent or independent, reclassified or discarded depending on the ability of a 
second formulation of drug to activate locomotion. (F) A still photo from a videotape of two 
assay plates. The larva (arrowheads) on the top and bottom plates have moved ~1 grid and 
3–4 grids respectively from the center of the plates. (G) Example of primary screen data. 
Drugs tested at both high (100uM, designated ‘H’) and low (10uM, designated ‘L’) 
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concentrations at 0, 2 and 24 hrs as indicated. Dotted line: 4.2 grids per 2 min, used as cut-
off for strong hits (e.g. 2F6-H).
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Figure 2. Primary screen hits
(A–D) Shown are the 40 of 1039 tested drugs that increased locomotion >3.5 SD above the 
mean (>4.2 grid lines per 2 min, see dotted line) at either 2 or 24 hr and either the low (L, 10 
uM) or high (H, 100uM) concentrations, labeled with the ID number from the Microsource 
library used for the primary screen. The drugs shown in panels A, B are listed (Table C, D) 
by their library ID number and their effective concentration (High or Low as in A, B, shown 
as ID–H or –L in the first column of C and D). The assay times (2 or 24 hrs after 
administration, or both times) at which the drug yielded a positive locomotor response is 
listed in the right hand column of C and D. (E) Model of larval locomotor circuit. The larval 
locomotor circuit remains incompletely defined; we show here a heuristic model of the 
minimal elements known to be present in the locomotor circuit as an aid for interpretating 
the results of the screen. Minimal elements of the circuit include (from right to left) the 
muscle expressing glutamate receptors (Glut receptor) innervated by a glutamatergic 
motoneuron (Glut motoneuron). Larval motoneurons express Ach receptors that stimulate 
their activity; they are therefore presumed to be innervated by a cholinergic interneuron but 
the identity and number of interneurons(s) is not known. Amines including octopamine and 
under some conditions dopamine are released onto yet to be identified cells (labeled 
“Interneurons”) to activate the central pattern generator (“CPG”) and thus stimulate 
locomotion. The cells included in the larval locomotor CPG are not yet clearly defined and 
the shading of the CPG reflects this ambiguity. It is possible that there are additional non-
aminergic inputs to the CPG capable of activating locomotion; these are indicated by “??”. 
Numbered arrows indicate possible sites of action for drugs including 1) upstream sits in the 
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CNS that activate the aminergic neurons, 2) DVMAT and/or proteins that regulate vesicular 
storage in the aminergic neurons, 3) the exocytotic release machinery of the aminergic 
neurons, 4) amine receptors including OA receptors for a activation of baseline locomotion, 
5) alternative amine-independent inputs (indicated by “??”), 6) Ach receptors. Targets 1–3 
would require presynaptic amine storage and are DVMAT dependent (see text). Targets 4–6 
would function independently of DVMAT and presynaptic amine storage.
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Figure 3. Validation assays
(A–C) Putative DVMAT independent drugs. 6 drugs stimulated locomotion in the weak 
expressor (A, top panel) but not the null (A, bottom panel) confirming DVMAT 
dependence. B) 3 failed to stimulate locomotion in either genotype. (C) 2 showed minimal 
activity in the weak expressor (C, top) but stimulated locomotion in the null (C, bottom, see 
text). (D–G) Validation of putative DVMAT independent drugs. 4 drugs stimulated 
locomotion in the weak expressor (D, top) and null (D, bottom) confirming DVMAT 
independence. Two drugs originally classified as DVMAT dependent stimulated locomotion 
in both the weak expressor (E, top panel) and the null (E) and were reclassified as DVMAT 
independent. (F) Betamethasone failed to stimulate locomotion was discarded. (G) 
Retesting “weak hits”. One drug (isopropamide) activated locomotion in the weak 
expressor (G, top) but not the null (G) and was classified as DVMAT dependent. Drugs 
were tested at two concentrations above the minimum that was effective in the primary and 
secondary screens: 10um, 100um and 1 mM or 100uM, 1mM and 10mM as indicated. 
Dotted line: cut-off for validated hits (3 SD above the mean at time 0 for all drugs tested in 
the weak expressor during the validation phase (3.6 grid lines/2 min), or 4 SD above mean at 
time 0 for all drugs tested in the null during the validation phase (2.2 grid lines/2 min). 
Abbreviations: Carbamaz., Carbamazepine; Dexameth., Dexamethasone.; Guaifen, 
Guaifenesin; Betameth., Betamethasone; Chlorprom., Chlorpromazine.
Lawal et al. Page 15
Mol Psychiatry. Author manuscript; available in PMC 2014 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 4. DVMAT dependent versus independent activities of selected drugs
(A) Pergolide increased locomotion in the null and weak expressor with a peak effect at 0.5 
mM but steadily reduced locomotion at higher concentrations. (B) Dacarbazine increased 
locomotion in the weak expressor but not the null with a peak effect at 0.5 mM, One-Way 
ANOVA, ***p<0.001, **0<0.01, *p<0.05. (C) Pergolide at 1mM partially rescued adult 
egg-laying in both the null and weak expressor. (two-way ANOVA p<0.0001. Bonferroni 
post test, ***p<0.001). (D) Dacarbazine (1mM) rescued egg-laying in the weak expressor 
but not the null (two-way ANOVA, Bonferroni post test, *p<0.05). For panels A–D, bars 
represent mean +/− SEM, n=16–20 larvae per condition. (Dashed lines boxes are a place 
marker for eggs laid by animals treated with vehicle alone; the actual value of the bar is 
zero). (E–H) Pergolide function requires OA signaling. (E) Treatment with mianserin. As 
compared to animals treated with vehicle for 2 hrs followed by vehicle for an additional 2 
hrs (Veh=>Veh), animals treated with 1 uM pergolide for 2 hrs followed by vehicle alone 
(Perg=>Veh) showed an increase in locomotion (For both panels E and F: two-way 
ANOVA, ***p<0.0001; Bonferroni post test, ***p<0.001, *p<0.05, n=6–12, error bars 
represent +/− SEM). Larvae fed pergolide then mianserin (0.25 mg/ml, Perg=>Mian) 
locomote less than larva fed pergolide followed by vehicle (Perg=>Veh). (F) Larvae fed 
pergolide then epinastine (Perg =>Epi) locomote less than larva fed pergolide then vehicle 
(Perg =>Veh) but more than controls (Veh=>Veh and Veh=>epinastine) suggesting partial 
rather than complete inhibition of pergolide’s effects by epinastine. (G, H) Dacarbazine but 
not pergolide requires presynaptic OA synthesis. (G) Dacarbazine (100 uM for 2 hrs) does 
not stimulate locomotion in the TbH mutant (HTbH −/−, two-way ANOVA p<0.05, 
Lawal et al. Page 16
Mol Psychiatry. Author manuscript; available in PMC 2014 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Bonferroni post test, ***p<0.001, n=6. (H) Pergolide (1uM, 2 hrs) stimulates locomotion in 
the TbH mutant (two-way ANOVA p<0.0001, Bonferroni post test, ***p<0.001). (I) 
Structures of dacarbazine, 5-amino-4- imimdazole-carboxamide-HCL (AICA) and 
aminoimidazole-4-carboxamide 1-β-D-ribofuranoside (AICAR). (J, K) Dose-dependent 
increase in locomotion in the dVMAT weak expressor fed AICA (panel J, 2 hrs, two-way 
ANOVA, p<0.0001. Bonferroni post test, *p<0.05, **p<0.01 as indicated) but not AICAR 
(panel K) (n=6–15 larvae per condition).
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Table 1
Validated Hits
Drug Known Use Class
1 Desipramine Antidepressant VMAT independent
2 Pergolide Dopamine receptor agonist ”
3 Carbachol Cholinergic ”
4 Carbamazepine Mood Stabilizer, Antiseizure ”
5 *Hydrastinine Antihemorrhagic ”
6 *Bethanechol Cholinergic ”
1 Imipramine Antidepressant VMAT dependent
2 Brucine Cholinergic ”
3 Hyoscyamine Anticholinergic ”
4 Isopropamide iodide Anticholinergic ”
5 Dacarbazine Chemotherapeutic ”
6 Norgesterol Contraceptive ”
7 Pindolol Beta blocker ”
Asterisk indicates drugs reclassified as DVMAT independent during validation.
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